Literature DB >> 33616746

Human glutathione peroxidase codon 198 variant increases nasopharyngeal carcinoma risk and progression.

Ala Laribi1, Sahar Aouf1, Sallouha Gabbouj1, Noureddine Bouaouinaa1,2, Abdelfattah Zakhama1,3, Hedi Harizi4,5.   

Abstract

PURPOSE: Glutathione peroxidase 1 (GPx-1) is a selenium-dependent detoxifying enzyme involved in the protection of cells against oxidative damage. Some genetic association studies reported significant associations between GPx-1 Pro198Leu variant and carcinogenesis across different populations; however, the impact of this variant on nasopharyngeal carcinoma (NPC) has not been explored. Therefore, the present study was planned to evaluate the potential involvement of the GPx-1 Pro198Leu variant and plasma GPx activity in the risk of developing NPC in a Tunisian population.
METHODS: The GPx-1 Pro198Leu genotype was determined in 327 NPC patients and 150 healthy controls by the RFLP-PCR analysis. The correlation between the GPx-1 variant and the clinicopathological parameters was examined. GPx activity was assessed in the plasma of 119 NPC patients and 58 healthy control subjects and according to GPx-1 genotypes and clinicopathological characteristics of NPC patients.
RESULTS: A significant association was found between GPx-1 Pro198Leu variant and NPC risk in a Tunisian population. The allelic frequencies of Pro and Leu alleles were 32% versus 68% and 41% versus 59% in NPC cases and controls, respectively. Thus, the minor 198 Leu allele increased significantly in NPC patients and appeared as a potential risk factor for NPC occurrence (OR = 1.48, CI 95% = 1.14-1.91, p = 0.002). The plasma GPx activity was significantly higher in NPC patients than in controls (p = 0.03). According to the clinicopathological characteristics of NPC patients, GPx activity decreased significantly in patients with lymph node metastasis (p = 0.004).
CONCLUSION: This is the first study showing a strong association between GPx-1 Pro198Leu genetic variant and NPC risk. GPx-1 Pro198Leu variant increased the development of regional lymph node metastasis. Plasma GPx activity was higher in NPC patients. Thus, GPx-1 gene could be considered as a determinant factor influencing NPC risk and progression.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  198Leu mutation; Clinicopathological parameters; Gpx-1 gene; Nasopharyngeal carcinoma; Plasma GPx activity

Mesh:

Substances:

Year:  2021        PMID: 33616746     DOI: 10.1007/s00405-021-06628-5

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  31 in total

Review 1.  Genetic predisposition factors and nasopharyngeal carcinoma risk: a review of epidemiological association studies, 2000-2011: Rosetta Stone for NPC: genetics, viral infection, and other environmental factors.

Authors:  Allan Hildesheim; Cheng-Ping Wang
Journal:  Semin Cancer Biol       Date:  2012-01-25       Impact factor: 15.707

2.  Nitrative and oxidative DNA damage as potential survival biomarkers for nasopharyngeal carcinoma.

Authors:  Yuan-Jiao Huang; Bei-Bei Zhang; Ning Ma; Mariko Murata; An-Zhou Tang; Guang-Wu Huang
Journal:  Med Oncol       Date:  2010-03-26       Impact factor: 3.064

Review 3.  Glutathione peroxidase.

Authors:  L Flohé
Journal:  Basic Life Sci       Date:  1988

4.  Contribution of Nitric oxide synthase 3 genetic variants to nasopharyngeal carcinoma risk and progression in a Tunisian population.

Authors:  Sahar Aouf; Ala Laribi; Sallouha Gabbouj; Elham Hassen; Noureddine Bouaouinaa; Abdelfattah Zakhama; Hedi Harizi
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-02-13       Impact factor: 2.503

Review 5.  Concurrent chemoradiotherapy in the management of advanced nasopharyngeal carcinoma: current status.

Authors:  Said Afqir; Nabil Ismaili; Hassan Errihani
Journal:  J Cancer Res Ther       Date:  2009 Jan-Mar       Impact factor: 1.805

6.  Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant.

Authors:  Yasushi Ichimura; Tomonori Habuchi; Norihiko Tsuchiya; Lizhong Wang; Chikara Oyama; Kazunari Sato; Hiroyuki Nishiyama; Osamu Ogawa; Tetsuro Kato
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

7.  ULK1: a promising biomarker in predicting poor prognosis and therapeutic response in human nasopharygeal carcinoma.

Authors:  Miao Yun; Hai-Yan Bai; Jia-Xing Zhang; Jian Rong; Hui-Wen Weng; Zhou-San Zheng; Yi Xu; Zhu-Ting Tong; Xiao-Xia Huang; Yi-Ji Liao; Shi-Juan Mai; Sheng Ye; Dan Xie
Journal:  PLoS One       Date:  2015-02-25       Impact factor: 3.240

8.  Nasopharyngeal carcinoma as a paradigm of cancer genetics.

Authors:  Malcolm J Simons
Journal:  Chin J Cancer       Date:  2011-02

9.  No association between TGF-β1 polymorphisms and risk of nasopharyngeal carcinoma in a large North African case-control study.

Authors:  Wafa Khaali; Khalid Moumad; El Khalil Ben Driss; Abdellatif Benider; Wided Ben Ayoub; Mokhtar Hamdi-Cherif; Kada Boualga; Elham Hassen; Marilys Corbex; Meriem Khyatti
Journal:  BMC Med Genet       Date:  2016-10-12       Impact factor: 2.103

10.  Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa.

Authors:  B-J Feng; M Khyatti; W Ben-Ayoub; S Dahmoul; M Ayad; F Maachi; W Bedadra; M Abdoun; S Mesli; H Bakkali; M Jalbout; M Hamdi-Cherif; K Boualga; N Bouaouina; L Chouchane; A Benider; F Ben-Ayed; D E Goldgar; M Corbex
Journal:  Br J Cancer       Date:  2009-09-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.